Skip to main content

Our progress on #FutureFresenius

  • We are progressing on our journey towards #FutureFresenius with a simplified structure, sharper focus and accelerated performance
  • We successfully completed the deconsolidation of Fresenius Medical Care - a landmark in the implementation of the #FutureFresenius program 
  • We place a clear focus on our Operating Companies Fresenius Kabi and Fresenius Helios: both have attractive market positions and excellent opportunities for profitable growth
  • We are actively managing our portfolio of assets where Fresenius lacks best ownership: our divestment program is well advancing
  • With our Fresenius Financial Framework, we set ambitious EBIT margin bands for our business segments
  • Fresenius Vamed’s transformation is progressing well with ongoing operational improvements
  • We significantly exceeded our Group cost saving target in 2023 by more than 40% and raised our 2025 structural productivity savings target 
Capital Markets Day Fresenius Helios

June 05, 2024
London, UK

Capital Markets Day Fresenius Helios

More information


“Fresenius has made an excellent start into the year and our focus on Fresenius Kabi and Fresenius Helios is paying off. We are confident to maintain our growth momentum and raise our outlook for the full year. With the exit from Vamed, our strategic portfolio restructuring is completed as planned. Fresenius is already a simpler, stronger, and more innovative company due to the consistent implementation of #FutureFresenius. We now have even more opportunities to offer world-class therapies and improve people’s health.

Michael Sen, Chairman of the Management Board




Social Media

By clicking “I consent” you consent to the activation of the activity feed on this website and the following processing of your personal data related to it according to Section 2 of the Privacy Statement